ArticleCurrent oncology (Toronto, Ont.)2022

Two Distinct Clinical Patterns of Ibrutinib-to-Venetoclax Transition in Relapsed Chronic Lymphocytic Leukemia Patients.

Isacco Ferrarini et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.